181 related articles for article (PubMed ID: 21129274)
1. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
[TBL] [Abstract][Full Text] [Related]
2. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
4. The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects.
Oboshi W; Watanabe T; Matsuyama Y; Kobara A; Yukimasa N; Ueno I; Aki K; Tada T; Hosoi E
Hum Immunol; 2016 Feb; 77(2):165-71. PubMed ID: 26582002
[TBL] [Abstract][Full Text] [Related]
5. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Hatjiharissi E; Xu L; Santos DD; Hunter ZR; Ciccarelli BT; Verselis S; Modica M; Cao Y; Manning RJ; Leleu X; Dimmock EA; Kortsaris A; Mitsiades C; Anderson KC; Fox EA; Treon SP
Blood; 2007 Oct; 110(7):2561-4. PubMed ID: 17475906
[TBL] [Abstract][Full Text] [Related]
6. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
[TBL] [Abstract][Full Text] [Related]
7. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
[TBL] [Abstract][Full Text] [Related]
8. [Fcγ receptorIIIa polymorphism in healthy children and those with hematological malignancies].
Qu YH; Li Y; Wu YF; Fang JP; Wei J; Huang SL; Ma XX; Huang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):959-62. PubMed ID: 20723308
[TBL] [Abstract][Full Text] [Related]
9. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
Taylor RJ; Chan SL; Wood A; Voskens CJ; Wolf JS; Lin W; Chapoval A; Schulze DH; Tian G; Strome SE
Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
[TBL] [Abstract][Full Text] [Related]
10. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
[TBL] [Abstract][Full Text] [Related]
11. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
[TBL] [Abstract][Full Text] [Related]
12. FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV.
Talathi SP; Shaikh NN; Pandey SS; Saxena VA; Mamulwar MS; Thakar MR
BMC Infect Dis; 2019 Dec; 19(1):1053. PubMed ID: 31842762
[TBL] [Abstract][Full Text] [Related]
13. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
14. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
15. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism.
Mishima Y; Terui Y; Mishima Y; Kuniyoshi R; Matsusaka S; Mikuniya M; Kojima K; Hatake K
Int Immunol; 2012 Aug; 24(8):477-83. PubMed ID: 22438420
[TBL] [Abstract][Full Text] [Related]
16. Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells.
Li Y; Huang K; Liu L; Qu Y; Huang Y; Wu Y; Wei J
Oncol Lett; 2019 Jan; 17(1):339-347. PubMed ID: 30655772
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
Capuano C; Romanelli M; Pighi C; Cimino G; Rago A; Molfetta R; Paolini R; Santoni A; Galandrini R
Cancer Res; 2015 Oct; 75(19):4097-108. PubMed ID: 26229120
[TBL] [Abstract][Full Text] [Related]
18. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
Terszowski G; Klein C; Stern M
J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
[TBL] [Abstract][Full Text] [Related]
19. Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
Trotta AM; Ottaiano A; Romano C; Nasti G; Nappi A; De Divitiis C; Napolitano M; Zanotta S; Casaretti R; D'Alterio C; Avallone A; Califano D; Iaffaioli RV; Scala S
Cancer Immunol Res; 2016 Apr; 4(4):366-74. PubMed ID: 26817995
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
